Membrane-associated RING-CH protein (MARCH8) is a novel glycolysis repressor targeted by miR-32 in colorectal cancer
Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the f...
Saved in:
Published in | Journal of translational medicine Vol. 20; no. 1; pp. 1 - 13 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
London
BioMed Central Ltd
05.09.2022
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
ISSN | 1479-5876 1479-5876 |
DOI | 10.1186/s12967-022-03608-z |
Cover
Loading…
Abstract | Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC. Method In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed. Results Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression. Conclusion In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC. Keywords: Colorectal cancer, Membrane-associated RING-CH protein 8 (MARCH8), Glycolysis, HK2, miR-32 |
---|---|
AbstractList | Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC.BACKGROUNDColorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC.In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed.METHODIn this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed.Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression.RESULTSSystematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression.In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC.CONCLUSIONIn summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC. Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC. In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed. Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression. In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC. Abstract Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC. Method In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed. Results Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression. Conclusion In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC. Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC. Method In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed. Results Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression. Conclusion In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC. Keywords: Colorectal cancer, Membrane-associated RING-CH protein 8 (MARCH8), Glycolysis, HK2, miR-32 Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of cancer cells, and disturbed metabolism showed clinical significance in CRC. The membrane-associated RING-CH 8 (MARCH8) protein, the first MARCH E3 ligase, plays an oncogenic role and serves as a prognostic marker in multiple cancers, however, the role of MARCH8 in CRC is unclear. In the present study, we aimed to investigate the biomarkers and their underlying mechanism for CRC. Method In this study, we first examined the function of MARCH8 in CRC by analysing public database. Besides, we performing gene silencing studies and generating cellular overexpression and xenograft models. Then its protein substrate was identified and validated. In addition, the expression of MARCH8 was investigated in tissue samples from CRC patients, and the molecular basis for decreased expression was analysed. Results Systematic analysis reveals that MARCH8 is a beneficial prognostic marker in CRC. In CRC, MARCH8 exhibited tumor-suppressive activity both in vivo and in vitro. Furthermore, we found that MARCH8 is negatively correlated with hexokinase 2 (HK2) protein in CRC patients. MARCH8 regulates glycolysis and promotes ubiquitination-mediated proteasome degradation to reduces HK2 protein levels. Then HK2 inhibitor partially rescues the effect of MARCH8 knockdown in CRC. Poised chromatin and elevated miR-32 repressed MARCH8 expression. Conclusion In summary, we propose that in CRC, poised chromatin and miR-32 decrease the expression of MARCH8, further bind and add ubiquitin, induce HK2 degradation, and finally repress glycolysis to promote tumor suppressors in CRC. |
ArticleNumber | 402 |
Audience | Academic |
Author | Zang, Yuan-Sheng Ye, Chen-Yang Wang, Zhan Wang, Miao-Miao Geng, Yan |
Author_xml | – sequence: 1 givenname: Zhan surname: Wang fullname: Wang, Zhan – sequence: 2 givenname: Miao-Miao surname: Wang fullname: Wang, Miao-Miao – sequence: 3 givenname: Yan surname: Geng fullname: Geng, Yan – sequence: 4 givenname: Chen-Yang surname: Ye fullname: Ye, Chen-Yang – sequence: 5 givenname: Yuan-Sheng surname: Zang fullname: Zang, Yuan-Sheng |
BookMark | eNp9kktrGzEUhYeS0jzaP9CVoJt0MamkGb02BWPa2JC0YNq10GjuuDIzI1eSA86vryZOSB1K0ULi6pzvci_nvDgZ_QhF8Z7gK0Ik_xQJVVyUmNISVxzL8v5VcUZqoUomBT_5631anMe4wZjWrFZvitOs5rXA_KxItzA0wYxQmhi9dSZBi1bLb9flfIG2wSdwI7q8na3mC_kRuYgMGv0d9Gjd763v9zGXAmwDZHdAyYQ1TIRmjwa3KiuKsj3rfACbTI-sGS2Et8XrzvQR3j3eF8XPr19-zBflzffr5Xx2U1pW41RSaXErLW-tsZK1LekqAg1jqpGCtbhSUHHVEaYwKMVYR7ExkjdAORWC87a6KJYHbuvNRm-DG0zYa2-cfij4sNYmJGd70FK1nMkGM8aqmlojm8pQajkmjeKMQGZ9PrC2u2aA1sKYgumPoMc_o_ul1_5Oq7rmQtQZcPkICP73DmLSg4sW-j4v3--ipoJgJSpS0Sz98EK68bsw5lVNKsYIxYQ9q9YmD-DGzue-doLqmSCcMqrY1PbqH6p8WhiczYHqXK4fGeTBYIOPMUCnrUsmOT-N5XpNsJ7Spw_p0zl9-iF9-j5b6Qvr03r-Y_oD5-va9A |
CitedBy_id | crossref_primary_10_1186_s10020_023_00684_9 crossref_primary_10_1007_s12291_023_01175_8 crossref_primary_10_1186_s13578_023_01100_9 crossref_primary_10_3390_v16121935 crossref_primary_10_1016_j_prp_2025_155909 crossref_primary_10_1186_s12943_024_02046_3 crossref_primary_10_1007_s10555_024_10201_x crossref_primary_10_3892_mmr_2025_13441 |
Cites_doi | 10.1016/j.nbt.2016.12.002 10.1371/journal.pone.0001852 10.18632/oncotarget.22602 10.1074/jbc.RA119.007508 10.1007/s00432-020-03172-3 10.1016/j.jprot.2021.104125 10.1038/onc.2017.31 10.1002/ijc.32104 10.3322/caac.21338 10.1038/s41467-019-10374-y 10.3390/cancers12061655 10.1159/000492882 10.1016/j.biopha.2018.07.050 10.1111/j.1743-7563.2012.01535.x 10.1084/jem.20160312 10.1016/j.cmet.2015.12.006 10.1038/nature07385 10.1016/S0140-6736(19)32319-0 10.18632/oncotarget.19658 10.1074/jbc.M112.448209 10.1007/s11626-019-00398-5 10.1001/jama.2021.0106 10.3892/ol.2012.928 10.2147/OTT.S228995 10.1002/ijc.32084 10.1038/oncsis.2017.57 10.1093/jnci/djz093 10.1074/jbc.M211285200 10.1002/ijc.33725 10.1186/s12935-017-0490-y 10.3322/caac.21590 10.1038/nchembio.971 10.1073/pnas.1205246109 10.1186/1476-4598-12-30 10.1016/j.cell.2012.02.065 10.3390/cancers13112550 10.3390/jcm9082419 10.1038/cr.2016.159 10.3389/fonc.2019.01207 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2022 BioMed Central Ltd. 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022. The Author(s). The Author(s) 2022 |
Copyright_xml | – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022. The Author(s). – notice: The Author(s) 2022 |
DBID | AAYXX CITATION 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1186/s12967-022-03608-z |
DatabaseName | CrossRef ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1479-5876 |
EndPage | 13 |
ExternalDocumentID | oai_doaj_org_article_89d658b0555342ca8b3a22c601b9651e PMC9446774 A716252954 10_1186_s12967_022_03608_z |
GeographicLocations | China United States--US |
GeographicLocations_xml | – name: China – name: United States--US |
GroupedDBID | --- 0R~ 29L 2WC 53G 5VS 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ TR2 TUS UKHRP WOQ WOW XSB ~8M PMFND 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c540t-28c0d8c6dcac85dd1f31eb559b875d039e369f1590e9955f20aa86be2627766d3 |
IEDL.DBID | M48 |
ISSN | 1479-5876 |
IngestDate | Wed Aug 27 01:23:46 EDT 2025 Thu Aug 21 13:41:36 EDT 2025 Fri Jul 11 01:14:04 EDT 2025 Fri Jul 25 02:25:34 EDT 2025 Tue Jun 17 21:11:14 EDT 2025 Tue Jun 10 20:50:30 EDT 2025 Tue Jul 01 02:59:36 EDT 2025 Thu Apr 24 22:59:47 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c540t-28c0d8c6dcac85dd1f31eb559b875d039e369f1590e9955f20aa86be2627766d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12967-022-03608-z |
PMID | 36064706 |
PQID | 2715512015 |
PQPubID | 43076 |
PageCount | 13 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_89d658b0555342ca8b3a22c601b9651e pubmedcentral_primary_oai_pubmedcentral_nih_gov_9446774 proquest_miscellaneous_2710973132 proquest_journals_2715512015 gale_infotracmisc_A716252954 gale_infotracacademiconefile_A716252954 crossref_citationtrail_10_1186_s12967_022_03608_z crossref_primary_10_1186_s12967_022_03608_z |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-09-05 |
PublicationDateYYYYMMDD | 2022-09-05 |
PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-05 day: 05 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London |
PublicationTitle | Journal of translational medicine |
PublicationYear | 2022 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | R Mclendon (3608_CR19) 2008; 455 T Ye (3608_CR28) 2019; 55 G Yang (3608_CR29) 2019; 9 W Wu (3608_CR30) 2013; 12 S Singh (3608_CR11) 2017; 17 J Liu (3608_CR44) 2020; 146 H Liang (3608_CR27) 2019; 12 J Yin (3608_CR36) 2018; 49 W Chen (3608_CR3) 2016; 66 NN Pavlova (3608_CR4) 2016; 23 R Chen (3608_CR24) 2012; 109 LH Biller (3608_CR9) 2021; 325 E Chen (3608_CR26) 2018; 106 I Cristobal (3608_CR31) 2020 HJ Lee (3608_CR42) 2019; 10 A Bar-Even (3608_CR23) 2012; 8 N Guo (3608_CR25) 2013; 9 J Fan (3608_CR35) 2017; 8 RL Siegel (3608_CR2) 2020; 70 Q Wang (3608_CR14) 2017; 6 F Chiara (3608_CR43) 2008; 3 J Yin (3608_CR13) 2018; 49 C Zhang (3608_CR16) 2019; 23 J Fan (3608_CR12) 2017; 8 LAM Cornelissen (3608_CR7) 2019; 144 J Liang (3608_CR22) 2017; 27 N Papadimitriou (3608_CR6) 2021; 149 AJ Franke (3608_CR8) 2019; 111 H Liu (3608_CR34) 2016; 213 R Myte (3608_CR5) 2019; 145 J Zheng (3608_CR37) 2012; 4 W Chen (3608_CR17) 2021 A Floridi (3608_CR20) 1981; 66 E Goto (3608_CR33) 2003; 278 E Dekker (3608_CR1) 2019; 394 S Singh (3608_CR15) 2021; 236 J Bauer (3608_CR10) 2017; 38 I Cristobal (3608_CR32) 2020 Y Shang (3608_CR39) 2017; 36 H Fujita (3608_CR40) 2013; 126 CH Chan (3608_CR38) 2012; 149 B van de Kooij (3608_CR41) 2013; 288 Y Li (3608_CR21) 2019; 294 X Zhang (3608_CR18) 2017; 8 |
References_xml | – volume: 38 start-page: 7 year: 2017 ident: 3608_CR10 publication-title: N Biotechnol doi: 10.1016/j.nbt.2016.12.002 – volume: 66 start-page: 497 year: 1981 ident: 3608_CR20 publication-title: J Natl Cancer Inst – volume: 3 start-page: e1852 year: 2008 ident: 3608_CR43 publication-title: PLoS ONE doi: 10.1371/journal.pone.0001852 – volume: 8 start-page: 108238 year: 2017 ident: 3608_CR12 publication-title: Oncotarget doi: 10.18632/oncotarget.22602 – volume: 294 start-page: 14745 year: 2019 ident: 3608_CR21 publication-title: J Biol Chem doi: 10.1074/jbc.RA119.007508 – volume: 146 start-page: 809 year: 2020 ident: 3608_CR44 publication-title: J Cancer Res Clin Oncol doi: 10.1007/s00432-020-03172-3 – volume: 236 start-page: 104125 year: 2021 ident: 3608_CR15 publication-title: J Proteomics doi: 10.1016/j.jprot.2021.104125 – volume: 8 start-page: 108238 year: 2017 ident: 3608_CR35 publication-title: Oncotarget doi: 10.18632/oncotarget.22602 – volume: 36 start-page: 4191 year: 2017 ident: 3608_CR39 publication-title: Oncogene doi: 10.1038/onc.2017.31 – volume: 145 start-page: 327 year: 2019 ident: 3608_CR5 publication-title: Int J Cancer doi: 10.1002/ijc.32104 – volume: 66 start-page: 115 year: 2016 ident: 3608_CR3 publication-title: CA Cancer J Clin doi: 10.3322/caac.21338 – volume: 10 start-page: 2625 year: 2019 ident: 3608_CR42 publication-title: Nat Commun doi: 10.1038/s41467-019-10374-y – year: 2020 ident: 3608_CR32 publication-title: Cancers doi: 10.3390/cancers12061655 – volume: 49 start-page: 306 year: 2018 ident: 3608_CR13 publication-title: Cell Physiol Biochem doi: 10.1159/000492882 – volume: 106 start-page: 1046 year: 2018 ident: 3608_CR26 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2018.07.050 – volume: 9 start-page: 6 year: 2013 ident: 3608_CR25 publication-title: Asia Pac J Clin Oncol doi: 10.1111/j.1743-7563.2012.01535.x – volume: 213 start-page: 1695 year: 2016 ident: 3608_CR34 publication-title: J Exp Med doi: 10.1084/jem.20160312 – volume: 23 start-page: 27 year: 2016 ident: 3608_CR4 publication-title: Cell Metab doi: 10.1016/j.cmet.2015.12.006 – volume: 49 start-page: 306 year: 2018 ident: 3608_CR36 publication-title: Cellular Physiol Biochem doi: 10.1159/000492882 – volume: 455 start-page: 1061 issue: 7216 year: 2008 ident: 3608_CR19 publication-title: Nature doi: 10.1038/nature07385 – volume: 394 start-page: 1467 year: 2019 ident: 3608_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(19)32319-0 – volume: 8 start-page: 82593 year: 2017 ident: 3608_CR18 publication-title: Oncotarget doi: 10.18632/oncotarget.19658 – volume: 288 start-page: 6617 year: 2013 ident: 3608_CR41 publication-title: J Biol Chem doi: 10.1074/jbc.M112.448209 – volume: 55 start-page: 812 year: 2019 ident: 3608_CR28 publication-title: In Vitro Cell Dev Biol Anim doi: 10.1007/s11626-019-00398-5 – volume: 325 start-page: 669 year: 2021 ident: 3608_CR9 publication-title: JAMA doi: 10.1001/jama.2021.0106 – volume: 23 start-page: 7482 year: 2019 ident: 3608_CR16 publication-title: Eur Rev Med Pharmacol Sci – volume: 4 start-page: 1151 year: 2012 ident: 3608_CR37 publication-title: Oncol Lett doi: 10.3892/ol.2012.928 – volume: 126 start-page: 2798 year: 2013 ident: 3608_CR40 publication-title: J Cell Sci – volume: 12 start-page: 9651 year: 2019 ident: 3608_CR27 publication-title: Onco Targets Ther doi: 10.2147/OTT.S228995 – volume: 144 start-page: 2290 year: 2019 ident: 3608_CR7 publication-title: Int J Cancer doi: 10.1002/ijc.32084 – volume: 6 start-page: e353 year: 2017 ident: 3608_CR14 publication-title: Oncogenesis doi: 10.1038/oncsis.2017.57 – volume: 111 start-page: 1131 year: 2019 ident: 3608_CR8 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djz093 – volume: 278 start-page: 14657 year: 2003 ident: 3608_CR33 publication-title: J Biol Chem doi: 10.1074/jbc.M211285200 – volume: 149 start-page: 1659 year: 2021 ident: 3608_CR6 publication-title: Int J Cancer doi: 10.1002/ijc.33725 – volume: 17 start-page: 116 year: 2017 ident: 3608_CR11 publication-title: Cancer Cell Int doi: 10.1186/s12935-017-0490-y – volume: 70 start-page: 7 year: 2020 ident: 3608_CR2 publication-title: CA Cancer J Clin doi: 10.3322/caac.21590 – volume: 8 start-page: 509 year: 2012 ident: 3608_CR23 publication-title: Nat Chem Biol doi: 10.1038/nchembio.971 – volume: 109 start-page: 14128 year: 2012 ident: 3608_CR24 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1205246109 – volume: 12 start-page: 30 year: 2013 ident: 3608_CR30 publication-title: Mol Cancer doi: 10.1186/1476-4598-12-30 – volume: 149 start-page: 1098 year: 2012 ident: 3608_CR38 publication-title: Cell doi: 10.1016/j.cell.2012.02.065 – year: 2021 ident: 3608_CR17 publication-title: Cancers doi: 10.3390/cancers13112550 – year: 2020 ident: 3608_CR31 publication-title: J Clin Med doi: 10.3390/jcm9082419 – volume: 27 start-page: 329 year: 2017 ident: 3608_CR22 publication-title: Cell Res doi: 10.1038/cr.2016.159 – volume: 9 start-page: 1207 year: 2019 ident: 3608_CR29 publication-title: Front Oncol doi: 10.3389/fonc.2019.01207 |
SSID | ssj0024549 |
Score | 2.4087458 |
Snippet | Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a... Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism is a hallmark of... Abstract Background Colorectal cancer (CRC) is the third most common cancer and leading cause of cancer-related deaths worldwide. Aberrant cellular metabolism... |
SourceID | doaj pubmedcentral proquest gale crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 1 |
SubjectTerms | Antibodies Antigens Biomarkers Breast cancer Cancer Cancer therapies Care and treatment Cell culture Chromatin Cloning Colorectal cancer Colorectal carcinoma Gene silencing Glycolysis Health aspects Hexokinase HK2 Medical prognosis Membrane proteins Membrane-associated RING-CH protein 8 (MARCH8) Membranes Metabolism Metastasis MicroRNA miR-32 Packaging Patients Plasmids Proteasomes Proteins Risk factors Survival analysis Tumor proteins Tumors Ubiquitin Ubiquitin-protein ligase Ubiquitination Xenografts |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA_SQ_EiWhVHq0QQVCQ0HzOZ5NiWlkVYD2Kht5BJMrqwnS27W6H9630vM7N0FPTidZIMyft-5OX3CHknkq2D4hHbt3NsYVYxE6Rlxqbghecq5F6H8y96dlF-vqwu77X6wpqwHh64J9yRsRGcZIO4VKqUwZtGeSkD5BGN1ZVIaH3B543J1IiyB2nP-ETG6KMNeDUwCFi5DhabG3Y3cUMZrf9Pm_x7neQ9x3P-mDwaIkZ63O_0CXmQugOyPx_uxJ-S7TxdQcrbJeYHUqdIscaBnc5ohmFYdPTDHG-FzEe62FBPu9XPtKTfl7cgBYhIQtd9PexqTfvKcPhDc0uvFl-ZkhSWI7Q1mkbYR0AxWT8jF-dn305nbOilwALEZFsmTeDRBB2DD6aKUbRKpAbSiQYSlsiVTUrbFmIbnqytqlZy741uktSyrrWO6jnZ61ZdekEoaHwl2ia1ooT0igfDSwVM8UqXrYipKogYSevCADSO_S6WLiccRrueHQ7Y4TI73F1BPu3WXPcwG3-dfYIc281EiOz8AQTHDYLj_iU4BXmP_HaoyLA9oEv_HgEOiZBY7hixtfI1aEEOJzNBAcN0eJQYNxiAjZM1xqIQXQE53u6GcSUWtXVpdZPnIFiSULIg9UTSJiebjnSLHxkE3EIeD6H7y_9Bilfkocy6YRmvDsnedn2TXkOstW3eZLX6BQyHIq8 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA86QXwRP7E6JYKgImH5aNPkSeZwXITrgzi4b6FN0nnhrt1674Ttr_ectPfOKuy1Sdo05yPn15z-DiHvRLSlVzxg-XaOJcwKZry0zNjoK1Fx5VOtw_l3PTvJvy2KxfjBbT2mVW59YnLUofP4jfxAlri5w3ZVfD6_YFg1Ck9XxxIad8k9pC5D8FUubgBXDuBn-6OM0Qdr2NvALWD-Ovhtbtj1ZDNKnP3_e-Z_syX_2n6OH5GHY9xIDwdBPyZ3YvuE3J-PJ-NPyWYezwD4tpFV44LHQDHTgR3NaCJjWLb0wxzPhsxHulzTirbd77iip6sr0AXkJaH9kBXb9XTID4c71Ff0bPmDKUlhOBJco4OEeXhUlv4ZOTn--vNoxsaKCsxDZLZh0ngejNfBV94UIYhGiVgDqKgBtgSubFTaNhDh8GhtUTSSV5XRdZRalqXWQT0ne23XxheEgt0XoqljI3IAWdwbnqtaVZXSeSNCLDIitkvr_Eg3jlUvVi7BDqPdIA4H4nBJHO46I592Y84Hso1be39Bie16IlF2utD1p260O2dsgBirRlozlUtfGZijlB5gaG11IWJG3qO8HZozTA_WZfgrAV4SibHcITJspcPQjOxPeoIZ-mnzVmPc6AbW7kZpM_J214wjMbWtjd1l6oOUSULJjJQTTZu82bSlXf5KVOAW0DwE8C9vf_gr8kAmrbeMF_tkb9NfxtcQS23qN8lg_gBTThsn priority: 102 providerName: ProQuest |
Title | Membrane-associated RING-CH protein (MARCH8) is a novel glycolysis repressor targeted by miR-32 in colorectal cancer |
URI | https://www.proquest.com/docview/2715512015 https://www.proquest.com/docview/2710973132 https://pubmed.ncbi.nlm.nih.gov/PMC9446774 https://doaj.org/article/89d658b0555342ca8b3a22c601b9651e |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9QwFA57AfFFvOLoOkQQfJBoLk2aPIjsLLsMwiwyODD4Eto0XQdnW-3MirO_3pO0M1pd9qUPTdKmOZd8pz39DkKvmDepE7QI5dtpKGEmiXbcEG28y1hGhYu1DifnajxLPs7lfA9tyx11C7i6MbQL9aRmzfLtrx-bD2Dw76PBa_VuBXsWmHvISwd_TDW53keHsDOloZTDJNF_uPdkhMMsSQ2R4Aa2P9HceI3eRhX5_P_32v9mUv61NZ3dR_c6TImPWyV4gPZ89RDdmXRfzR-hbxN_CUFx5UnWCcMXOGRBkJMxjkQNiwovVjjDVf3TL_HFcgPqEahKcNMmytYNblPGYWC-wZeLKREcw6jAeR18JtzeBf1pHqPZ2ennkzHpiiwQB2BtTbh2tNBOFS5zWhYFKwXzOcQZOUQyBRXGC2VKAD3UGyNlyWmWaZV7rniaKlWIJ-igqiv_FGFwBZKVuS9ZAnEXdZomIhdZJlRSssLLAWLbFbWuYyAPhTCWNkYiWtlWChakYKMU7PUAvdmN-d7yb9zaexQEtesZuLPjibq5sJ0pWm0KgF15YDoTCXeZhjly7iAyzY2SzA_Q6yBmG3QOpgfr0v6oAA8ZuLLscSDdit9HB-io1xMs0_Wbt4pit4pteRpAKsAuWI6Xu-YwMmS7Vb6-in0CixITfIDSnoL1nqzfUi2-RnZwAwE-YPpnt8_tObrLo7IbQuUROlg3V_4FwKt1PkT76TwdosPR6fmn6TC-pBhGO4LjdPTlNzBjIsA |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiKcIFDASCBCymth52AeE2tJqS7srVLVSb27iOGWlbVKyW9D2R_EbmXGSLQGpt15jO7E973j8DSFvAqsSI_wcy7f7WMIsYtJwxaSyJg1SXxhX63A0jodH4dfj6HiF_O7uwmBaZacTnaLOK4P_yNd5gsYdzFX0-fwHw6pReLraldBo2GLPLn5ByDb7tPsF6PuW853tw60ha6sKMAPeyZxxafxcmjg3qZFRngeFCGwGjnUGrnvuC2VFrAqw8r5VKooK7qepjDPLY54kcZwLeO8tshoKcBUGZHVze_zt4ArdD8Kt7mqOjNdnYE1BEWHGPFgKX7LLnvlzVQL-twX_5mf-ZfB27pN7radKNxrWekBWbPmQ3B61Z_GPyHxkzyDULi1LWxLbnGJuBdsaUgf_MCnp-xGeRskPdDKjKS2rn3ZKT6cL4D5EQqF1k4db1bTJSIc3ZAt6NjlgglMYjpDaqJJhHgbZs35Mjm5kt5-QQVmV9imhoGmioMhsEYQQ1vlG-qHIRJqKOCyC3EYeCbqt1aYFOMc6G1PtAh0Z64YcGsihHTn0pUc-LsecN_Ae1_beRIoteyI0t3tQ1ae6lXQtVQ5eXYZAaiLkJpUwR84NBL6ZiqPAeuQd0lujAoHpwb409yBgkQjFpTcQ08sdv3pkrdcTBN_0mzuO0a3imekrMfHI62UzjsRkutJWF64PgjQFgnsk6XFab2X9lnLy3YGPqxBMaxI-u_7jr8id4eFoX-_vjveek7vcSYBifrRGBvP6wr4AT26evWzFh5KTm5bYP_PFWP4 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Membrane-associated+RING-CH+protein+is+a+novel+glycolysis+repressor+targeted+by+miR-32+in+colorectal+cancer&rft.jtitle=Journal+of+translational+medicine&rft.au=Wang%2C+Zhan&rft.au=Wang%2C+Miao-Miao&rft.au=Geng%2C+Yan&rft.au=Ye%2C+Chen-Yang&rft.date=2022-09-05&rft.pub=BioMed+Central+Ltd&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-022-03608-z&rft.externalDocID=A716252954 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon |